Precigen (PGEN) Secures FDA Approval for Papillomatosis Treatment

Precigen, Inc. (NASDAQ:PGEN) is one of the best multibagger penny stocks to buy according to analysts. On August 15, the stock exploded by more than 70% after the US Food and Drug Administration approved PAPZIMEOS for treating adults with recurrent respiratory papillomatosis (RRP).

The rally in the market came as the approval made PAPZIMEOS the first and only FDA-approved therapy for adult RRP patients. The FDA approved the treatment option without requiring Precigen to conduct a confirmatory clinical trial, despite the initial submission being made under an accelerated approval pathway.

“With the landmark FDA approval of PAPZIMEOS and broad label, all adult RRP patients are now eligible for access to the first and only approved therapy that targets the root cause of the disease,” said Helen Sabzevari, President and CEO of Precigen.

Precigen has established Papzimeos SUPPORT, a patient support program offering services including insurance navigation and financial assistance. The program is part of the company’s push to promote the newly FDA-approved treatment.

Precigen, Inc. (NASDAQ:PGEN) is a biopharmaceutical company that focuses on developing and commercializing gene and cell therapies using precision medicine technologies. They are dedicated to addressing complex diseases in immuno-oncology, autoimmune disorders, and infectious diseases.

While we acknowledge the potential of PGEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Tech Stocks with Strong Return on Equity and 13 Best NYSE Penny Stocks to Invest in Now.

Disclosure: None. This article is originally published at Insider Monkey.